Peoples Bank KS Has $819,000 Stock Holdings in Sanofi (NASDAQ:SNY)

Peoples Bank KS trimmed its stake in shares of Sanofi (NASDAQ:SNY) by 2.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,985 shares of the company’s stock after selling 355 shares during the quarter. Peoples Bank KS’s holdings in Sanofi were worth $819,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Barrow Hanley Mewhinney & Strauss LLC boosted its position in Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC boosted its holdings in shares of Sanofi by 1,153.1% in the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after acquiring an additional 2,306,286 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after acquiring an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans grew its position in Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after acquiring an additional 1,424,289 shares during the last quarter. Finally, Federated Hermes Inc. increased its holdings in Sanofi by 26.5% during the 2nd quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after purchasing an additional 673,172 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Up 1.4 %

Shares of SNY opened at $49.87 on Wednesday. The business’s fifty day moving average price is $48.95 and its two-hundred day moving average price is $52.11. The firm has a market capitalization of $126.56 billion, a price-to-earnings ratio of 25.44, a PEG ratio of 1.23 and a beta of 0.57. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter last year, the business earned $2.55 earnings per share. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, analysts predict that Sanofi will post 4.06 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on SNY shares. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Sanofi has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.